drugset / Trial / NCT00000823
A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection
Phase 2
Completed
85 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Bristol-Myers Squibb · collabGlaxo Wellcome · collab
Treatment
Summary
To determine the relative antiviral activity and safety of zidovudine ( AZT ) and didanosine ( ddI ) alone and in combination, as well as in various sequences of administration. The relative efficacy of the approved antiretrovirals in early HIV-1 disease is unclear; thus, a study is needed to evaluate the ability of these various nucleoside analogs to limit pathogenicity.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2000-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Didanosine | Small molecule | — | — |
| Subject | Zidovudine | Small molecule | — | — |